Study of intracellular signaling pathways in Chronic Myeloproliferative Neoplasms / / Serena Martinelli.
A gain-of-function mutation in Janus kinase 2 (JAK2V617F) is at the basis of the majority of chronic myeloproliferative neoplasms (MPN). Enhanced activation of other downstream pathways including the PI3K/mTOR pathway has been documented as well. In this study we evaluated the effects of JAK1/2 inhi...
Saved in:
| Superior document: | Premio Tesi di Dottorato |
|---|---|
| VerfasserIn: | |
| Place / Publishing House: | Florence : : Firenze University Press,, 2017. |
| Year of Publication: | 2017 |
| Language: | English |
| Series: | Premio tesi di dottorato.
|
| Physical Description: | 1 online resource (80 pages). |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| id |
993603852204498 |
|---|---|
| ctrlnum |
(CKB)5860000000047424 (NjHacI)995860000000047424 (EXLCZ)995860000000047424 |
| collection |
bib_alma |
| record_format |
marc |
| spelling |
Martinelli, Serena, author. Study of intracellular signaling pathways in Chronic Myeloproliferative Neoplasms / Serena Martinelli. Florence : Firenze University Press, 2017. 1 online resource (80 pages). text txt rdacontent computer c rdamedia online resource cr rdacarrier Premio Tesi di Dottorato Description based on publisher supplied metadata and other sources. A gain-of-function mutation in Janus kinase 2 (JAK2V617F) is at the basis of the majority of chronic myeloproliferative neoplasms (MPN). Enhanced activation of other downstream pathways including the PI3K/mTOR pathway has been documented as well. In this study we evaluated the effects of JAK1/2 inhibitors, alone and in combination with mTOR, with a dual mTOR/PI3K inhibitor and with a pan PI3K inhibitor in in-vitro and in-vivo MPN models. Our findings of strong synergy between the JAK2 inhibitors and mTOR/PI3K inhibitor suggested that we might be able to administer these drugs at lower concentrations than when the drugs are used individually. This provides a framework for combination trials using compounds in patients with myeloproliferative neoplasms. English. Molecular biology. 88-927-3168-8 Premio tesi di dottorato. |
| language |
English |
| format |
eBook |
| author |
Martinelli, Serena, |
| spellingShingle |
Martinelli, Serena, Study of intracellular signaling pathways in Chronic Myeloproliferative Neoplasms / Premio Tesi di Dottorato |
| author_facet |
Martinelli, Serena, |
| author_variant |
s m sm |
| author_role |
VerfasserIn |
| author_sort |
Martinelli, Serena, |
| title |
Study of intracellular signaling pathways in Chronic Myeloproliferative Neoplasms / |
| title_full |
Study of intracellular signaling pathways in Chronic Myeloproliferative Neoplasms / Serena Martinelli. |
| title_fullStr |
Study of intracellular signaling pathways in Chronic Myeloproliferative Neoplasms / Serena Martinelli. |
| title_full_unstemmed |
Study of intracellular signaling pathways in Chronic Myeloproliferative Neoplasms / Serena Martinelli. |
| title_auth |
Study of intracellular signaling pathways in Chronic Myeloproliferative Neoplasms / |
| title_new |
Study of intracellular signaling pathways in Chronic Myeloproliferative Neoplasms / |
| title_sort |
study of intracellular signaling pathways in chronic myeloproliferative neoplasms / |
| series |
Premio Tesi di Dottorato |
| series2 |
Premio Tesi di Dottorato |
| publisher |
Firenze University Press, |
| publishDate |
2017 |
| physical |
1 online resource (80 pages). |
| isbn |
88-927-3168-8 |
| callnumber-first |
Q - Science |
| callnumber-subject |
QH - Natural History and Biology |
| callnumber-label |
QH506 |
| callnumber-sort |
QH 3506 M378 42017 |
| illustrated |
Not Illustrated |
| dewey-hundreds |
500 - Science |
| dewey-tens |
570 - Life sciences; biology |
| dewey-ones |
572 - Biochemistry |
| dewey-full |
572.8 |
| dewey-sort |
3572.8 |
| dewey-raw |
572.8 |
| dewey-search |
572.8 |
| work_keys_str_mv |
AT martinelliserena studyofintracellularsignalingpathwaysinchronicmyeloproliferativeneoplasms |
| status_str |
n |
| ids_txt_mv |
(CKB)5860000000047424 (NjHacI)995860000000047424 (EXLCZ)995860000000047424 |
| carrierType_str_mv |
cr |
| hierarchy_parent_title |
Premio Tesi di Dottorato |
| is_hierarchy_title |
Study of intracellular signaling pathways in Chronic Myeloproliferative Neoplasms / |
| container_title |
Premio Tesi di Dottorato |
| _version_ |
1796653259607244800 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01786nam a2200313 i 4500</leader><controlfield tag="001">993603852204498</controlfield><controlfield tag="005">20230517171436.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">230517s2017 it o 000 0 eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5860000000047424</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)995860000000047424</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995860000000047424</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">QH506</subfield><subfield code="b">.M378 2017</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">572.8</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Martinelli, Serena,</subfield><subfield code="e">author.</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Study of intracellular signaling pathways in Chronic Myeloproliferative Neoplasms /</subfield><subfield code="c">Serena Martinelli.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Florence :</subfield><subfield code="b">Firenze University Press,</subfield><subfield code="c">2017.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (80 pages).</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Premio Tesi di Dottorato</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on publisher supplied metadata and other sources.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">A gain-of-function mutation in Janus kinase 2 (JAK2V617F) is at the basis of the majority of chronic myeloproliferative neoplasms (MPN). Enhanced activation of other downstream pathways including the PI3K/mTOR pathway has been documented as well. In this study we evaluated the effects of JAK1/2 inhibitors, alone and in combination with mTOR, with a dual mTOR/PI3K inhibitor and with a pan PI3K inhibitor in in-vitro and in-vivo MPN models. Our findings of strong synergy between the JAK2 inhibitors and mTOR/PI3K inhibitor suggested that we might be able to administer these drugs at lower concentrations than when the drugs are used individually. This provides a framework for combination trials using compounds in patients with myeloproliferative neoplasms.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Molecular biology.</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">88-927-3168-8</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Premio tesi di dottorato.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-06-09 12:41:18 Europe/Vienna</subfield><subfield code="f">System</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-06-08 16:08:14 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337727880004498&Force_direct=true</subfield><subfield code="Z">5337727880004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337727880004498</subfield></datafield></record></collection> |